top of page

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

A possible addition to endometrial cancer treatments today.

New England Journal of MedicineDostarlimab endometrial Cancer

June 8, 2023

N Engl J Med 2023; 388:2145-2158 DOI: 10.1056/NEJMoa2216334


The addition of Dostarlimab for endometrial cancer being added to current cancer treatment follows:

“Endometrial cancer is the sixth most common cancer women worldwide and the second most common type of gynecologic cancer. Carboplatin plus paclitaxel is standard chemotherapy for first-line treatment of primary advanced or recurrent endometrial cancer; however, long-term outcomes remain poor, with median overall survival of less than 3 years."

"CONCLUSIONS: Dostarlimab plus carboplatin–paclitaxel significantly increased progression-free survival among patients with primary advanced or recurrent endometrial cancer, with a substantial benefit in the dMMR–MSI-H population."

"Long-term outcomes are poor with standard first-line chemotherapy for primary advanced or recurrent endometrial cancer. Whether adding immunotherapy could improve outcomes is uncertain. New research findings are summarized in a short video."

Click below to play:



bottom of page